Merck & Company (MRK)

Jan 17, 2025, 9:58 AM EST - 12 hours ago

What's In Store For Merck Stock In 2025?

Jan 16, 2025, 6:45 AM EST - 1 day ago

Merck to Hold Fourth-Quarter and Full-Year 2024 Sales and Earnings Conference Call Feb. 4

Jan 14, 2025, 8:13 PM EST - 3 days ago

Merck CEO Robert Davis goes one-on-one with Jim Cramer

Jan 14, 2025, 8:08 PM EST - 3 days ago

We've seen patients on transplant lists taken off of them after starting Winrevair, says Merck CEO

Jan 14, 2025, 7:52 PM EST - 3 days ago

Long-term possibilities in healthcare are unbelievable, says Jim Cramer

ABT CAH LLY REGN

Jan 14, 2025, 6:57 PM EST - 3 days ago

Jim Cramer says he supports healthcare stocks for their long-term value

LLY REGN

Jan 14, 2025, 6:52 PM EST - 3 days ago

Merck CEO talks medicines beyond the company's top cancer drug

Jan 14, 2025, 11:56 AM EST - 3 days ago

The Big 3: PEP, AVAV, MRK

AVAV PEP

Jan 14, 2025, 10:37 AM EST - 3 days ago

Merck & Co. Inc. (MRK) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)

Jan 13, 2025, 6:10 PM EST - 4 days ago

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

ABBV AMGN AZN BNTX FBCG GILD GSK

Jan 12, 2025, 12:30 PM EST - 5 days ago

3 Dividend Stocks for January 2025

CMCSA UPS

Jan 11, 2025, 7:25 AM EST - 6 days ago

3 Ideal Buys From 51 'Safer' Dividends In 100 January Barron's Sustainable Dogs

AVNT BBY BEN ES EXC HAS HPQ

Jan 10, 2025, 9:00 AM EST - 7 days ago

Atropos Health Collaborates with Merck for Rapid Evidence Generation to Accelerate Innovation for Life-Saving Treatments

Jan 8, 2025, 11:13 AM EST - 9 days ago

Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market

AMGN BBIO BMY IOVA LLY MDGL PFE

Jan 8, 2025, 9:57 AM EST - 9 days ago

There's a ‘Shadow' Over Biotech Stocks. Why It Isn‘t All Bad News.

MRNA PFE

Jan 8, 2025, 6:48 AM EST - 9 days ago

Merck's GARDASIL® Receives Expanded Approval for Males in China

Jan 7, 2025, 11:42 PM EST - 9 days ago

Merck says its HPV vaccine for men was approved by China's drug regulator

Jan 7, 2025, 1:36 AM EST - 10 days ago

WuXi Biologics to Sell Irish Vaccine Facility to Merck for $500 Million

Jan 6, 2025, 7:50 AM EST - 11 days ago

China's WuXi Biologics to sell Ireland vaccine facility to Merck for $500 million

Jan 6, 2025, 6:45 AM EST - 11 days ago

Merck to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Jan 4, 2025, 11:49 AM EST - 13 days ago

Big Blue Chip Dividends? Try These ‘Dogs' Up To 6.8%

AMGN CSCO CVX IBM JNJ KO MCD

Jan 2, 2025, 12:21 PM EST - 15 days ago

January Dow Dogs: 1 'Safer' Buy, And 5 With Promise

AMGN BA CRM CSCO CVX DIS GS

Dec 31, 2024, 7:48 AM EST - 17 days ago

UK approves Merck's therapy for rare lung condition

Dec 25, 2024, 9:00 AM EST - 23 days ago

Top 7 Blue-Chip Stocks With The Best Return Potential Going Into 2025

AMZN CAT CVX JNJ SHW UNH

Dec 23, 2024, 6:43 PM EST - 25 days ago

Merck to discontinue drug for bacterial infection

Dec 23, 2024, 9:00 AM EST - 25 days ago

Merck: A Low-Hanging Fruit To Pick

Dec 22, 2024, 2:51 PM EST - 26 days ago

Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More

LLY

Dec 20, 2024, 2:05 PM EST - 4 weeks ago

Stocks on the Move: Uber, Carmax, Novo Nordisk, Eli Lilly, Merck, Crown Castle and Accenture

ACN CCI KMX LLY NVO UBER

Dec 20, 2024, 6:45 AM EST - 4 weeks ago

Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody

Dec 19, 2024, 11:54 AM EST - 4 weeks ago

Stock Of The Day: Where Does The Merck Downtrend End?

Dec 19, 2024, 8:32 AM EST - 4 weeks ago

Merck: Healthcare Pharma Giant: 3.2% Yield, 9.3% 5-Year Dividend Growth, Buy Time

Dec 19, 2024, 6:59 AM EST - 4 weeks ago

Merck's HIV treatment meets main goal of two late-stage studies

Dec 19, 2024, 6:45 AM EST - 4 weeks ago

Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection

Dec 18, 2024, 12:02 PM EST - 4 weeks ago

Merck's weight-loss pill deal: what it means for Eli Lilly

LLY

Dec 18, 2024, 10:25 AM EST - 4 weeks ago

Merck Licenses a Weight-Loss Pill. It's Bad News for Obesity Biotechs.

Dec 18, 2024, 7:59 AM EST - 4 weeks ago

Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing deal

Dec 18, 2024, 6:59 AM EST - 4 weeks ago

Merck signs up to $2 bln obesity drug deal with Chinese biotech Hansoh

Dec 18, 2024, 6:45 AM EST - 4 weeks ago

Merck Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist

Dec 17, 2024, 6:45 AM EST - 4 weeks ago

Merck Announces FDA Acceptance of Biologics License Application for Clesrovimab, an Investigational Long-Acting Monoclonal Antibody Designed to Protect Infants from RSV Disease During their First RSV Season

Dec 17, 2024, 5:24 AM EST - 4 weeks ago

Merck: Buy Opportunity Backed By Growth

Dec 16, 2024, 4:38 PM EST - 4 weeks ago

Merck discontinues development of 2 cancer drugs after trial failures

Dec 16, 2024, 4:30 PM EST - 4 weeks ago

Merck Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab

Dec 16, 2024, 6:45 AM EST - 4 weeks ago

Merck's KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy After Surgery as Adjuvant Treatment for Patients With Resectable Stage II, IIIA or IIIB NSCLC

Dec 16, 2024, 12:35 AM EST - 4 weeks ago

Merck Has Become Very Cheap Again

Dec 13, 2024, 7:05 AM EST - 5 weeks ago

Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) as Treatment for Adult Patients With Certain Types of Von Hippel-Lindau Disease-Associated Tumors and for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma

Dec 12, 2024, 11:35 AM EST - 5 weeks ago

14 Upcoming Dividend Increases

AIN CARR ECL EFSC EMN FNF HI

Dec 12, 2024, 7:35 AM EST - 5 weeks ago

2 Ideal Buys From 50 'Safer' Dividends In 100 December Sustainables

AGR APD AWK BAC BALL BBY BEN

Dec 11, 2024, 10:22 AM EST - 5 weeks ago

LYNPARZA® (olaparib) Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase 3 Trial

Dec 9, 2024, 6:45 AM EST - 5 weeks ago

Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced Epithelial Ovarian Cancer

Dec 8, 2024, 3:00 PM EST - 5 weeks ago

Merck's Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse Large B-Cell Lymphoma